Recent Company News

• 03:40 PM ET Dec 14, 2025
  

  CSL downgraded to neutral from outperform at Macquarie (A$183.93, 0.00)

• 12:06 PM ET Dec 07, 2025
  

  CSL presents, publishes five-year results from HOPE-B study of HEMGENIX (A$184.10, 0.00)

• 12:01 PM ET Dec 07, 2025
  

  Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years

• 07:57 AM ET Nov 18, 2025
  

  CSL to invest ~$1.5B in the U.S. over 5 years to grow manufacturing of plasma-derived therapies

• 06:48 PM ET Nov 10, 2025
  

  Street Takeaways - CSL Capital Markets Day

• 06:34 PM ET Nov 06, 2025
  

  Akebia Therapeutics presentation of a post-hoc win odds analysis of all-cause mortality and hospitalization from the Phase 3 INNO2VATE trials of vadadustat at ASN Kidney Week ($2.01, 0.00)

• 08:10 AM ET Nov 05, 2025
  

  Transcript Intelligence: CSL Capital Markets Day (A$175.40, 0.00)

• 05:14 PM ET Nov 04, 2025
  

  CSL publishes presentation for today's Capital Markets Day (A$176.99, 0.00)

• 11:58 PM ET Oct 28, 2025
  

  StreetAccount Summary: Australia and New Zealand Stocks reaching new 52-week highs/lows (39 total)

• 08:43 PM ET Oct 28, 2025
  

  StreetAccount Summary - Trading higher/lower: Australia & New Zealand midday